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Chronic viral infections represent a major burden to human health, and modulation of the immune
system is emerging as a novel approach to fighting such infections. Pellegrini et al. (2011) demon-
strate that treatment with the cytokine IL-7 may reinvigorate the immune response to persistent
infection by targeting immunosuppressive Socs3 proteins.Persistent infection with viruses such as
human immunodeficiency virus (HIV) and
hepatitis C virus (HCV) causes debilitating
illness associated with high rates of
mortality and morbidity. While long-term
viral persistence can often be attributed
to viral evasion of the immune system, it
is now evident that host-derived immuno-
suppressive processes also actively
disrupt viral clearance. T cells represent
a key effector arm of the immune system
required for virus control. However,
during certain chronic viral infections,
some antiviral T cells fail to survive,
leaving holes in the T cell repertoire,
whereas others persist in a dysfunctional
or ‘‘exhausted’’ state with impaired
effector functions (Zajac et al., 1998).
Strikingly, a host program of immunosup-
pression that involves immunological
signaling molecules (cytokines) such as
IL-10 and TGF-b, as well as inhibitory
receptors like PD-1, directs such T cell
dysfunction (Barber et al., 2006; Brooks
et al., 2006; Ejrnaes et al., 2006; Tinoco
et al., 2009).
Though it may seem counterintuitive to
dampen immune responsiveness to an
ongoing infection, this process likely
evolved to limit the tissue destruction
that would result from an unregulated
immune response against a widely
disseminated virus. Nevertheless, tran-
sient interference with these inhibitory
pathways has clear therapeutic benefits,
given that it improves T cell function and
lowers viral titers in animal models (Barber
et al., 2006; Brooks et al., 2006; Ejrnaes
et al., 2006; Tinoco et al., 2009). However,lethal immunopathology can arise if the
timing of treatment is wrong (Barber
et al., 2006), demonstrating that boosting
the immune response can come at a cost.
Therefore, the ideal immunotherapy
would act to boost the immune response
while limiting any collateral damage to
host tissues. In this issue, Pellegrini et al.
(2011) demonstrate that administration
of the cytokine IL-7 leads to viral control
during chronic infection through its ability
to simultaneously augment the T cell
response and induce factors that limit
tissue destruction. IL-7 treatment has
the added benefit of boosting overall
T cell numbers, a feature that could help
to counter the low T cell numbers associ-
ated with HIV-induced acquired immuno-
deficiency syndrome (AIDS).
Though IL-7 is known primarily for its
role in promoting survival and homeo-
stasis of naive and memory T cells, past
work by the authors demonstrated that
IL-7 also boosts effector functions within
T cells. The authors speculated that IL-7
administration during chronic viral infec-
tion might similarly improve antiviral T cell
function and facilitate viral clearance. To
test this hypothesis, they administer IL-7
to mice infected with lymphocytic chorio-
meningitis virus (LCMV) clone13, a power-
ful animal model of chronic viral infection
that recapitulates many aspects of persis-
tent virus infection in humans. The authors
observe a dramatic effect, with acceler-
ated virus clearance due to a large boost
in both the numbers and functionality of
antiviral T cells. Surprisingly, the animals
survive this immune onslaught withoutCell 144,detectable organ damage, at least as
assessed by examining liver damage.
More impressively, the treatment is effec-
tive despite beginning at day 8 postinfec-
tion, when virus levels peak and antiviral
T cell responses begin showing signs of
exhaustion.
The profound impact of IL-7 treatment
on the immune response is likely multifac-
torial. Given the known role of IL-7 in T cell
survival, the authors first examine the
effect of IL-7 on overall T cell numbers
and find that IL-7 drives an expansion of
the entire pool of T cells, in part due to
an increase in T cell production by the
thymus. However, their work suggests
that the increase in thymic output of
T cells probably does not contribute to
the elevation in virus-specific T cell
numbers, but rather, this stems from other
effects. Nevertheless, the effect of IL-7
was dependent on T cells, given that
depletion of T cells (but not B cells)
ablates the response induced by IL-7.
The authors also examine changes in
cytokine levels after IL-7 treatment and
find a large shift in the cytokine profile,
most notably an increase in the levels of
IL-6 and IL-17, a decrease in immunosup-
pressive TGF-b, and an increase in the
tissue-protective cytokine IL-22. IL-6
appears to be a key cytokine in this
context, given that it is required for both
the enhanced immune response and the
cytoprotective effects of IL-7 treatment.
Furthermore, the elevated IL-22 secretion
is dependent on IL-6, and the authors
subsequently find that IL-22 plays a key
role in the prevention of liver destruction.February 18, 2011 ª2011 Elsevier Inc. 467
Figure 1. Effects of IL-7 during Chronic Viral Infection
Pellegrini et al. (2011) demonstrate that chronic viral infection (left) promotes
high expression of Socs3, a negative regulator of immune cytokine signaling, in
antiviral T cells. Socs3 impairs T cell function and promotes T cell ‘‘exhaus-
tion,’’ leading to viral persistence. Treatment with the cytokine IL-7 (right)
blocks Socs3 induction in antiviral T cells, thereby promoting effector func-
tions and viral clearance. IL-7 likely acts on CD4+ T cells to promote IL-17
secretion, which in turn induces IL-6 production. IL-6 promotes survival and
function of antiviral T cell by an unknownmechanism. IL-7 also promotes IL-22
secretion, which protects against tissue destruction by the elevated immune
response. IL-7 may also act directly on the antiviral CD4 and CD8 T cells (not
shown). All of these factors lead to viral clearance without adverse immuno-
pathology. In addition to its antiviral effect, IL-7 also boosts thymic production
of naive T cells. The elevated thymic output could help to counter lower T cell
levels during chronic HIV infection.These results thus explain
how IL-6 prevents tissue
destruction, but they don’t
explain how IL-6 promotes
the T cell response.
Next, the authors investi-
gate potential mechanisms
by which IL-6 may boost the
immune response. They first
show that the effects of IL-7
do not depend on regulatory
T cells, a cell type known to
suppress activated T cell
function. Instead, they spec-
ulate that IL-7 may alter the
responsiveness of T cells to
IL-6. They test this idea by
measuring the levels of
suppressor of cytokine
signaling 3 (Socs3), a protein
known to modulate IL-6
responsiveness. Indeed,
they find higher Socs3 levels
in T cells derived from mice
with chronic versus acute
LCMV infection. Further-more, IL-7 treatment lowers the amount
of Socs3 within T cells, possibly via AKT
and FOXO signaling. Perhaps most
importantly, selective ablation of Socs3
in T cells causes early virus clearance
and recapitulates many of the effects of
IL-7 treatment. These data demonstrate
a role for Socs3 in limiting T cell respon-
siveness during chronic viral infection
and implicate IL-7 treatment as a potential
therapeutic approach for interfering with
this pathway (Figure 1).
This study provides exciting clues as to
how the immune response is regulated
during chronic infection and how we
may manipulate regulatory pathways
therapeutically. A number of questions
remain, however. First, the exact mecha-
nism by which IL-7 treatment causes
IL-6 upregulation remains unclear. The
authors note an increase in both CD4+
T cells that produce IL-17 (Th17 cells)
and serum IL-17 after IL-7 treatment.
Given that Socs3 is an inhibitor of Th17
differentiation, they hypothesize that the
reduction in Socs3 levels caused by IL-7
permits greater numbers of Th17 cells to
develop. An increase in Th17 cells, in
turn, likely induces IL-6 production,
consistent with previous experiments468 Cell 144, February 18, 2011 ª2011 Elsev(Ogura et al., 2008). Such a model
predicts that IL-17 is required for the up-
regulation of IL-6 upon IL-7 treatment,
an idea that needs testing. Furthermore,
it will be important to determine whether
the Th17 cells are virus specific or derived
from another source.
Second, it is unclear how IL-6
signaling and Socs3 deficiency conspire
to elevate the antiviral T cell response.
Socs3 loss could cause altered IL-6
signaling in antiviral T cells (Johnston
and O’Shea, 2003), thereby boosting
their survival and function. However, it
is unlikely that IL-7 and IL-6 signaling is
direct, given that IL-6 and IL-7 receptors
are transcriptionally repressed in virus-
specific T cells during clone 13 infection
(Wherry et al., 2007). The cause of
elevated Socs3 expression in untreated
mice during chronic infection is also of
interest. The inhibitory cytokine IL-10
is a likely candidate because IL-10 sig-
naling induces Socs3 expression, and
IL-10 deficiency has effects on chronic
viral infection similar to those caused
by IL-7 treatment (Brooks et al., 2006;
Ejrnaes et al., 2006).
Finally, the study suggests that Th17
cells may protect against virus infection.ier Inc.Although Th17 cells have
been previously associated
with better control of influ-
enza infection (McKinstry
et al., 2009), Th17 cells are
typically linked to antifungal
and antibacterial immunity.
Further work will be required
to determine the exact role
of these cells in antiviral
immunity. Ultimately, this
study suggests that IL-7
treatment holds great
promise for controlling
chronic viral infections, such
as those caused by HIV and
hepatitis B and C viruses,
which together infect and
afflict more than 10% of the
world’s population.REFERENCES
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